Frankfurt - Delayed Quote EUR

Kenvue Inc. (J4D.F)

Compare
21.98 +0.46 (+2.14%)
At close: November 15 at 3:29 PM GMT+1
Loading Chart for J4D.F
DELL
  • Previous Close 21.52
  • Open 21.80
  • Bid 22.52 x --
  • Ask 22.76 x --
  • Day's Range 21.80 - 21.98
  • 52 Week Range 16.08 - 21.98
  • Volume 5
  • Avg. Volume 142
  • Market Cap (intraday) 42.851B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 42.27
  • EPS (TTM) 0.52
  • Earnings Date Feb 6, 2025 - Feb 10, 2025
  • Forward Dividend & Yield 0.78 (3.53%)
  • Ex-Dividend Date Nov 13, 2024
  • 1y Target Est --

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

www.kenvue.com

22,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: J4D.F

View More

Performance Overview: J4D.F

Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

J4D.F
20.13%
S&P 500
23.08%

1-Year Return

J4D.F
31.11%
S&P 500
30.58%

3-Year Return

J4D.F
7.02%
S&P 500
41.93%

5-Year Return

J4D.F
7.02%
S&P 500
41.93%

Compare To: J4D.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: J4D.F

View More

Valuation Measures

Annual
As of 11/15/2024
  • Market Cap

    43.37B

  • Enterprise Value

    50.75B

  • Trailing P/E

    42.08

  • Forward P/E

    18.90

  • PEG Ratio (5yr expected)

    2.12

  • Price/Sales (ttm)

    2.88

  • Price/Book (mrq)

    4.17

  • Enterprise Value/Revenue

    3.46

  • Enterprise Value/EBITDA

    20.88

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.88%

  • Return on Assets (ttm)

    6.50%

  • Return on Equity (ttm)

    9.88%

  • Revenue (ttm)

    15.46B

  • Net Income Avi to Common (ttm)

    1.06B

  • Diluted EPS (ttm)

    0.52

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.06B

  • Total Debt/Equity (mrq)

    82.93%

  • Levered Free Cash Flow (ttm)

    1.52B

Research Analysis: J4D.F

View More

Company Insights: J4D.F

Research Reports: J4D.F

View More